TG Therapeutics, Inc. TGTX R2K

Q: What is the current share price of TG Therapeutics, Inc. (TGTX)?

As of 2026-07-14 21:23 PDT, TG Therapeutics, Inc. (TGTX) trades at $54.89 on NasdaqCM. Its 52-week range is $26.39 to $59.06.

Q: What is the market capitalisation of TGTX?

TG Therapeutics, Inc. (TGTX) has a market capitalisation of $8.40B on NasdaqCM.

Q: What is the P/E ratio of TGTX?

TGTX trades at a trailing price-to-earnings (P/E) ratio of 19.19. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 12.04.

Q: What is the return on equity (ROE) of TGTX?

TGTX has a return on equity (ROE) of 112.60%. Its return on capital employed (ROCE) is 13.56%.

Q: Is TGTX a good stock to buy?

This page provides a data-driven analysis of TG Therapeutics, Inc. (TGTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.tgtherapeutics.com

Company Profile ↓

$54.89

+41.03% 1Y

Mkt Cap$8.40B

P/E19.19

P/B12.04

52W High$59.06

52W Low$26.39

Book Value$4.11

EPS (TTM)$2.86

Company Overview

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 112.6%, reflecting efficient use of shareholder capital.

Steady Revenue Expansion

Revenue has grown at a 151.7% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 19.2, below the sector median of 25.4.

Healthy Margins

Maintains a net profit margin of 66.0%.

Recent Developments

Dec 2025 Revenue of $616.29M (+87.3% YoY); net profit $447.18M.
Trailing 12 Months Year-on-year growth — revenue +69.6%, earnings +300.0%.
5-Year Trend Long-term compounding — revenue CAGR 151.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	151.70%
1 Year:	69.60%

Compounded Profit Growth

5 Years:	-
1 Year:	300.00%

Stock Price Performance

1 Year:	+41.03%
6 Months:	+92.80%
3 Months:	+62.44%
1 Month:	+14.24%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 87% of range

$26.39 $59.06

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)59.35 · Neutral

Price Performance

1M+14.24%

3M+62.44%

6M+92.80%

1Y+41.03%

Valuation vs Sector

P/E of 19.19 is below the sector median of 25.41 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 112.6%.
Excellent profit margin of 66.0%.
Compounding revenue at 151.7% over 5 years.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

19.19

Industry PE

25.41

Forward P/E

19.11

PEG Ratio

1.61

Book Value

$4.11

Price to Book

12.04

P/S

10.82

EV/EBITDA

48.52

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

151.70%

Profit 5Y

Revenue (YoY)

69.60%

Earnings (YoY)

300.00%

Profitability & Returns

ROCE

13.56%

ROE

112.60%

ROA

8.55%

Profit Margin

65.95%

Op Margin

16.98%

Gross Margin

83.05%

EPS (Latest Qtr)

$0.12

EPS (TTM)

$2.86

Balance Sheet & Liquidity

Debt/Equity

1.29

Quick Ratio

4.84

Current Ratio

5.81

Debt

$753.56M

Total Assets

$1.53B

Current Assets

$630.76M

Working Capital

$477.00M

Ownership

Promoter Holding

7.47%

Chg in Prom Hold

FII / Inst Holding

70.24%

Chg in FII Hold

0.00%

Financial Snapshot

Enterprise Value

$8.40B

Total Revenue (TTM)

$700.35M

EBITDA

$149.58M

Free Cash Flow

$-30.16M

Operating Cash Flow

$-13.95M

Shares Outstanding

153.08M

Gross Margin

83.05%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	TGTX TG Therapeutics, Inc. R2K	54.89	19.19	$8.40B	0.00%	13.56%	112.60%	151.70%	-
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.02M	594.00K	94.00K	7.80M	16.07M	165.81M	63.47M	73.47M	83.88M	120.86M	141.15M	161.71M	192.57M	204.92M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.54M	18.94M	28.09M	38.14M	33.51M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	105.31M	122.21M	133.62M	154.43M	171.41M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	96.69M	87.37M	104.25M	103.94M	136.61M
Operating Income	-14.60M	-17.11M	-13.83M	-	-13.99M	-16.02M	-24.93M	-	-27.67M	-28.43M	-31.59M	-	-41.58M	44.34M	-34.33M	-	-34.69M	-35.54M	-60.86M	-	-50.24M	-50.84M	-85.72M	-89.20M	-77.49M	-85.13M	-66.87M	-38.94M	-34.96M	-36.99M	-44.67M	114.78M	-9.27M	8.82M	12.43M	8.62M	34.84M	29.36M	50.49M	34.80M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.28M	37.70M	32.69M	51.69M	28.11M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.76M	6.72M	6.72M	6.53M	7.67M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.47M	30.92M	25.91M	45.09M	20.36M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	408.00K	2.73M	-364.99M	22.06M	586.00K
Net Income	-14.58M	-17.10M	-13.66M	-17.61M	-13.85M	-15.90M	-24.83M	-23.67M	-27.73M	-28.35M	-31.54M	-30.86M	-41.53M	-44.14M	-33.95M	-53.86M	-35.16M	-36.21M	-61.93M	-39.57M	-	-	-	-	-	-	-69.01M	-40.51M	-35.82M	-39.23M	-47.61M	113.93M	-10.71M	6.88M	3.88M	5.06M	28.19M	390.89M	23.04M	19.78M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.69	-0.59	-0.65	-0.51	-0.30	-0.26	-0.28	-0.34	0.73	-0.07	0.04	0.02	0.03	0.17	2.43	0.14	0.12
R&D Expense	9.62M	11.26M	11.57M	-	11.62M	13.53M	21.80M	-	22.68M	26.71M	27.15M	-	35.02M	38.70M	33.40M	-	32.38M	32.87M	57.98M	-	36.02M	36.45M	50.46M	63.09M	44.87M	51.97M	48.04M	26.87M	20.80M	15.87M	28.12M	14.75M	32.72M	17.56M	20.14M	46.36M	31.78M	40.88M	-	48.40M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	152.00K	152.00K	152.00K	152.00K	152.00K	6.69M	2.79M	233.66M	329.00M	616.29M
Operating Income	-881.97K	-26.90M	-22.97M	-55.72M	-63.18M	-78.97M	-118.71M	-174.40M	-169.06M	-273.59M	-344.77M	-218.32M	20.63M	41.93M	123.32M
Net Income	-853.07K	-18.07M	-20.48M	-	-	-	-	-	-	-	-348.10M	-223.81M	12.67M	23.38M	447.18M
Diluted EPS	-	-	-	-	-	-	-	-	-	-2.42	-2.63	-1.65	0.09	0.15	2.77
R&D Expense	327.28K	21.03M	13.66M	40.09M	47.71M	69.23M	102.53M	159.39M	154.18M	165.90M	222.58M	125.35M	76.19M	94.29M	160.22M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Nov 2011	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	14.54M	22.07M	48.11M	86.75M	113.47M	54.78M	97.38M	83.62M	163.01M	625.64M	-	193.57M	329.59M	577.69M	1.06B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	168.27M	317.94M	566.36M	630.76M
Cash & Equivalents	0	0	0	9.75M	16.46M	40.49M	55.71M	55.06M	25.03M	56.72M	41.96M	112.64M	553.44M	-	102.30M	92.93M	179.89M	79.15M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	39.82M	110.46M	125.59M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	51.09M	129.19M	305.63M
Total Liabilities	-	-	-	4.90M	6.52M	8.06M	6.65M	11.90M	18.91M	30.39M	59.58M	124.40M	106.29M	-	134.99M	169.09M	355.33M	415.23M
Current Liabilities	-	-	-	1.61M	2.22M	6.32M	5.12M	10.53M	16.88M	27.96M	38.85M	84.45M	87.55M	-	53.20M	53.72M	90.68M	153.76M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	0	28.97M	7.72M	-	71.14M	100.12M	244.43M	245.65M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	83.06M	110.80M	253.72M	253.71M
Total Equity	-	0	-	9.62M	15.55M	40.05M	80.10M	101.57M	35.87M	66.99M	24.04M	38.62M	519.35M	-	58.59M	160.50M	222.36M	648.02M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	146.43M	151.47M	156.20M	158.85M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-86.58K	-5.27M	-	-	-	-	-93.76M	-128.93M	-132.81M	-214.51M	-295.63M	-176.17M	-31.41M	-40.52M	-24.77M
Investing Cash Flow	10.39K	8.99K	-	-	-	-	-8.21M	1.18M	-718.00K	-24.51M	-332.00K	-20.01M	-50.65M	-1.04M	13.80M
Financing Cash Flow	9.82M	21.72M	-	-	-	-	133.66M	113.64M	204.21M	679.83M	41.42M	-391.00K	72.70M	128.53M	-89.73M
Capital Expenditure	-0	-1.40K	-5.68K	-18.57K	-42.22K	-344.00K	-2.00K	-90.00K	-131.00K	-357.00K	-401.00K	-14.00K	-0	-45.00K	-214.00K
Free Cash Flow	-86.58K	-5.28M	-	-	-	-	-93.76M	-129.01M	-132.94M	-214.86M	-296.04M	-176.18M	-31.41M	-40.56M	-24.99M
Share Buybacks	-	84.54K	149.80K	0	0	-	-	-	-	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-51,953.3%	-78,100.0%	-114,736.8%	-111,220.4%	-179,996.1%	-5,154.3%	-7,839.0%	8.8%	12.7%	20.0%
Net Margin %	-	-	-	-	-	-	-	-	-	-	-5,204.1%	-8,036.3%	5.4%	7.1%	72.6%
ROE %	-8.9%	-116.2%	-51.1%	-	-	-	-	-	-	-	-	-382.0%	7.9%	10.5%	69.0%
ROCE %	-6.8%	-135.4%	-54.9%	-68.3%	-61.4%	-208.3%	-171.0%	-389.6%	-215.2%	-50.8%	-	-155.5%	7.5%	8.6%	13.6%

Shareholding Pattern

Insiders

7.47%

Institutions

70.24%

Public Float

75.91%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	14.54%	22.25M	$1.23B
2	State Street Corporation	5.65%	8.65M	$479.15M
3	Vanguard Portfolio Management LLC	5.40%	8.27M	$458.34M
4	Vanguard Capital Management LLC	4.31%	6.60M	$365.79M
5	Soleus Capital Management, L.P.	2.63%	4.03M	$223.20M
6	Geode Capital Management, LLC	2.29%	3.50M	$193.88M
7	ClearBridge Investments, LLC	2.10%	3.21M	$177.87M
8	Goldman Sachs Group Inc	1.49%	2.29M	$126.73M
9	Congress Asset Management Co	1.42%	2.17M	$120.10M
10	Jane Street Group, LLC	1.33%	2.04M	$113.10M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TGTX

Google News hu, 09 Jul 2026

TG Therapeutics (TGTX) Stock May Still Be Cheap Despite New Trial News - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOa01wUHhFd3J6QWVia3VpWkNGclBQSzZiRTRHM0E3MktUSlR2TkliYmY5VTh5Y1Nrc0U2ckxzTFNGWnhQeTg2WE9NZXdINGJwT1ctUmlERDZNajZMalozOWVTMFNSRDNmMUlzRjV6N3FWVUpENzFqR0dXWnNfY3A4OXVkek5IcHg2VG9qTz…

Google News Wed, 17 Jun 2026

TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxONnRkaGZyWC1KaXZKcmFBTTFlYnh6aDJiT0Vpb0FVd3JpWUN6dHFSSVh1MlFfQXN2TTdzMjFINlpSQ1lCc2NSOW05Q2gzNE9vaERyVzZYc3piZXR4Slpvc2JUQWRmUjlkZWs2eUpLanV4aW9YYm1CSTY4bU9xTjF2dnlwWVg4Sll2S1JTWH…

Google News hu, 18 Jun 2026

The Utter Rampage That Sent This Biotech Flying 79% - Investor's Business Daily

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQdUU0NUs0blRCUXdPNmZTQUw2OFpydnpBN0daZnFJd0pIRjZTbHFLczlqTXB0TDBsZ0tyb19fSXlCNFRBdjNpTmlSTFpyY1NUQnZIU0hFRk1CaVRjcTZEd2JyRk5NRUFCdEZMOG1tb2s1MlJINFp5S1NWaVQ2TVA3UzlJTF9ZbEpERUM3ST…

Google News Mon, 13 Jul 2026

TGTX Maintained by HC Wainwright & Co. -- Price Target Raised to $77 - GuruFocus

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNbUdZLUtBMWNpcHBFeHI1TGNFa0FrUmVRTWdtYUVuWGZZMzZUakNEeFk3cVRhUnlwRkMxdG9udy04b0ZjNnZQbC0wXzVpNHlJMnk5UHJyTW5wR2FscUx2eTVTWU1xQ0RZdVBBajVhNDcwdTFjMmJ4OEpKcGVhN01FeFZSb2tzNWtMZ0g3Ql…

Google News Sun, 12 Jul 2026

Is TG Therapeutics (TGTX) Fully Valued Following Its New Schizophrenia Trial Launch? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxOalRraGIzNWFnSnBMSElJYlcyZ1c0cFhKRnJoQTJMOHh4a1VheUdyeWdzUmZCOUhKQmxMRE1HR19BWTd3WDRhbkNTRXh6N1B3Yk9QOEVJNWhpSlM1TUlvYnV5N1JOaUNRYUY0VnVDdk1JYjVQbTlpMEZKVDB0bmd2VEIxelNJeC1OU1UxY2…

Google News ue, 23 Jun 2026

TG Therapeutics Stock 10-Day Winning Spree: Stock Climbs 35% - Trefis

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUTdiOFVVRUhqV3B0eHp5M0poaVpxZWszcF9pT0tEQTczYVZaQTA5Wm16d3BsVlk5TWZEd2R3RGdnOWJhQktQcl9JQWtrOUlnRkV5eFdXVE0tOFJXVnk1SHlzVGV6ZjZtZGdXUVYwTVRKc09EcElQaDhMTFlaMm0yYU9xbFV0VXVTUGxsZG…

TGTX — Frequently Asked Questions

What is the current share price of TG Therapeutics, Inc. (TGTX)?

As of 2026-07-14 21:23 PDT, TG Therapeutics, Inc. (TGTX) trades at $54.89 on NasdaqCM. Its 52-week range is $26.39 to $59.06.

What is the market capitalisation of TGTX?

TG Therapeutics, Inc. (TGTX) has a market capitalisation of $8.40B on NasdaqCM.

What is the P/E ratio of TGTX?

TGTX trades at a trailing price-to-earnings (P/E) ratio of 19.19. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 12.04.

What is the return on equity (ROE) of TGTX?

TGTX has a return on equity (ROE) of 112.60%. Its return on capital employed (ROCE) is 13.56%.

Is TGTX a good stock to buy?

This page provides a data-driven analysis of TG Therapeutics, Inc. (TGTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

TG Therapeutics, Inc. TGTX R2K

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

TG Therapeutics (TGTX) Stock May Still Be Cheap Despite New Trial News - Yahoo Finance

TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data - Stocktwits

The Utter Rampage That Sent This Biotech Flying 79% - Investor's Business Daily

TGTX Maintained by HC Wainwright & Co. -- Price Target Raised to $77 - GuruFocus

Is TG Therapeutics (TGTX) Fully Valued Following Its New Schizophrenia Trial Launch? - simplywall.st

TG Therapeutics Stock 10-Day Winning Spree: Stock Climbs 35% - Trefis

TGTX — Frequently Asked Questions

What is the current share price of TG Therapeutics, Inc. (TGTX)?

What is the market capitalisation of TGTX?

What is the P/E ratio of TGTX?

What is the return on equity (ROE) of TGTX?

Is TGTX a good stock to buy?

Explore More